We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
By Joe Hoppe
Pharma giant Pfizer Inc. has been fined 63.0 million pounds ($75.6 million) by the U.K. markets regulator for overcharging the country's National Health Service for a life-saving epilepsy drug.
Flynn Pharma Ltd. was also fined GBP6.7 million for charging what the Competition and Markets Authority described as unfairly high prices for phenytoin sodium capsules for more than four years, with the ultimate cost borne by the NHS, the regulator said in a statement dated Thursday.
The CMA said the companies debranded the drug--formerly known as Epanutin--so that it was no longer subject to price regulation and allowing them to set prices at their discretion. As Pfizer and Flynn were the dominant U.K. suppliers of the drug at the time, the NHS had no choice but to pay the inflated final price, the regulator said.
Over four years Pfizer charged prices between 780% and 1,600% higher than previously, the CMA said. The company supplied the drug to Flynn, which sold the capsules on to pharmacies and wholesalers for 2,300%-2,600% higher than previously, the regulator said.
NHS annual costs for phenytoin capsules rose from GBP2 million in 2012 to around GBP50 million the following year, according to the regulator.
Neither Pfizer nor Flynn Pharma were immediately available for comment.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
July 22, 2022 04:22 ET (08:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions